Business Wire - January 18, 2000
STGI is firmly convinced that we can bring our own contribution, with our ANTICORT(TM)drug, in trying to help this catastrophe of unheard of proportions.
Our belief is based, among others, on the potential capability of ANTICORT to easily cross the immune cell membrane, thus attacking the HIV/AIDS virus within the cell. There is no present medication that has been able to attack the AIDS virus inside the cell. Indeed reports published in the medical press show that it is within these cells that the AIDS virus can comfortably hide, undisturbed by all medication in use at the present time , and can come out later, at any time, to re-infect the body. Research reports suggest that the virus can still be alive even after 60 (sixty) years of present medication; and reports also suggest that even vaccines, if and when developed, might not be able to do anything about this problem.
In this respect, we believe that this is a fitting time to remind our readers about our News Release of Nov. 17, 1999 titled "The ultimate battle against HIV/AIDS will be fought inside the immune cells."
In a potential collaborative project, STGI would supply a tentative budget, the Protocol (identical to the one submitted to the FDA), sufficient supplies of ANTICORT(TM) and know-how. The South Africa partner would offer qualified personnel, facilities and financing.
For interested parties, please contact: Alfred T. Sapse M.D., President & CEO, 101 Convention Center Drive, Suite 310, Las Vegas, Nevada 89109, USA; Tel: 702/734-6413; Fax: 702/733-9505; E-mail: asapse@aol.com.
NOTE: Safe harbor statement under the private securities litigation reform act of 1995: This release contains forward-looking statements that could differ from actual results. The statements are subject to risk and uncertainties, including, but not limited to, the impact of competition, fluctuations in stock price and liquidity, fluctuating operating results and other risks detailed from time to time in the company filings with the securities and exchange commission.
STGI is pursuing the world wide development and distribution of its drug, ANTICORT , which is currently in the clinical trial process as an anticortisol, steroidogenesis inhibitor drug for the treatment of immune deficency in AIDS/HIV+ and other diseases such as Aging, Cancer and Depression.
CONTACT: STGI Janet Greeson, 702/222-1988 or Performance Strategies, Inc. Messrs. Richard L. Brown/Chuck Jordan, 303/948-3601
000118
BW000104
Copyright © 2000 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .